Esophageal cancer researchers reported a mechanism for resistance to anti-PD-1 therapy: tumor-produced SIRPα contributes both to tumor growth and T-cell exhaustion. The study supports combination strategies rather than single-agent checkpoint reliance, tying mechanistic immunology directly to treatment design. In oncology biology more broadly, a review mapped how ferroptosis can become either a liability or a weapon in cancer microenvironments—emphasizing the pathway’s dependence on iron handling and immune signaling context. That framing points to therapy-resistance risk as well as opportunity for targeted modulation. For drug developers, these findings reinforce that immune checkpoint outcomes increasingly require pathway-level diagnostics—identifying which tumors can circumvent checkpoint blockade through immune exhaustion circuits or death-pathway rewiring.